Covid trials


Using their vast experience in other research and trials systems, CRCTU has successfully transferred this knowledge to trials in Covid-19 during the recent pandemic. 


OCTAVE is a multi-disease, observational, cohort trial that will seek to understand the immune response to SARS-CoV-2 vaccinations in patients with certain immunosuppressed conditions.


OCTAVE-DUO is a multi-disease, randomised clinical trial to determine whether a re-boost vaccine strategy can induce an immune response in clinically vulnerable patients with proven inadequate response to SARS-CoV-2 vaccine.


CATALYST is a collaborative phase II adaptive platform trial set up in response to the Coronavirus Disease 2019 (COVID-19) pandemic. We work with intensive care, respiratory and inflammatory researchers across the UK to rapidly trial new treatments for UK patients hospitalised with severe COVID-19.


COVD19_BMT is a prospective non interventional study to evaluate the role of immune and inflammatory response in recipients of allogeneic haematopoietic stem cell transplantation (SCT) affected by severe COVID19 infection.


PACE is an epidemiological study into the impact of COVID-19 on patients with Acute Myeloid Leukaemia (AML) undergoing chemotherapy